Completely steroid-free immunosuppression in liver transplantation: A randomized study

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 463-471

  Ramirez, Carlo B ^a   Doria, Cataldo ^a   Frank, Adam M ^a   Armenti, Stephen T ^b   Marino, Ignazio R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Calcineurin inhibitors; Corticosteroids; Enteric coated mycophenolic acid; Hepatitis C recurrence; Liver transplantation

Indexed keywords

BASILIXIMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PEGINTERFERON; PREDNISONE; RIBAVIRIN; TACROLIMUS; TRIMETHOPRIM SULFATE; VALGANCICLOVIR; CORTICOSTEROID; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLON HEMORRHAGE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; GUNSHOT INJURY; HEPATIC ARTERY THROMBOSIS; HEPATITIS C; HEPATOPULMONARY SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG CANCER; MAINTENANCE THERAPY; MONOTHERAPY; NASOGASTRIC TUBE; NEUTROPENIA; PEROPERATIVE CARE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETRANSPLANTATION; SEPSIS; SURVIVAL RATE; TREATMENT DURATION; WEIGHT GAIN; ADOLESCENT; ADULT; AGED; FEMALE; GRAFT REJECTION; LIVER DISEASES; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TACROLIMUS; YOUNG ADULT;

EID: 84878645990     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12119     Document Type: Article

References (44)

1. Starzl TE, Marchioro TL, Porter KA et al. Homotransplantation of the liver. Transplantation 1967: 5(Supplement): 790.
2. Gane E, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996: 110: 167.
3. Fukumoto T, Berg T, Ku Y et al. Viral hemodynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996: 24: 1351.
4. Greig P, Lilly L, Scudamore C et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003: 9: 587.
5. Belli LS, De Carlis L, Rondinara G et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998: 27: 1524.
6. Stegall MD, Wachs ME, Everson G et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997: 64: 1755.
7. Eason JD, Loss GE, Blazek J et al. Steroid free liver transplantation using RATG: results of a prospective randomized trial. Liver Transpl 2001: 7: 693.
8. Tisone G, Angelico M, Palmieri G et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999: 67: 1308.
9. Reding R, Gras J, Sokal E et al. Steroid free liver transplantation in children. Lancet 2003: 362: 2068.
10. Pirenne J, Aerts R, Koshiba T et al. Steroid-free immunosuppression during and after liver transplantation-a 3-yr follow-up report. Clin Transplant 2003: 17: 177.
11. Marino IR, Doria C, Scott V et al. Efficacy and safety of basiliximab with a tacrolimus based regimen in liver transplant recipients. Transplantation 2004: 78: 886.
12. Demetris AJ, Batts KP, Dhillon AP et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997: 25: 658.
13. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991: 13: 372.
14. Brunt EM. Grading and staffing the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000: 31: 241.
15. Everson GT, Trouillot T, Wachs M et al. Steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999: 5: S4.
16. Fasola CG, Klintmalm GB. Hepatitis C recurrence after liver transplantation: in search of the optimal immunosuppression to improve outcome. Curr Opin Organ Transplant 2006: 11: 637.
17. Belli LS, Alberti AB, Rondinara GF et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplant Proc 2001: 33: 1353.
18. Kato T, Yoshida H, Sadfar K et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005: 37: 1217.
19. Llado L, Xiol X, Figueras J et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006: 44: 710.
20. Pelletier SJ, Vanderwall K, Debroy MA et al. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc 2005: 37: 1214.
21. Reggiani P, Arru M, Regazzi M et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc 2005: 37: 1697.
22. Filipponi F, Callea F, Salizzoni M et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV- liver transplant recipients given basiliximab-steroids or basiliximab-placebo, in addition to cyclosporine and azathioprine. Transplantation 2004: 78: 1488.
23. Ringe B, Braun F, Schütz E et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001: 71: 508.
24. Margarit C, Bilbao I, Castells L et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005: 18: 1336.
25. Boillot O, Mayer DA, Boudjema K et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005: 11: 61.
26. Langrehr JM, Neumann UP, Lang M et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002: 34: 1565.
27. Lerut JP. Avoiding steroids in solid organ transplantation. Transpl Int 2003: 16: 213.
28. Kotsch K, Ulrich F, Reutzel-Selke A et al. Methylprednisolone therapy in deceased donor reduces inflammation in the donor liver and improves outcome after liver transplantation. Ann Surg 2008: 248: 1042.
29. Sileri P, Schena S, Fukuda J et al. Corticosteroids enhance hepatic injury following ischemia-reperfusion. Transplant Proc 2001: 33: 3712.
30. Debonera F, Krasinkas AM, Gelman AE et al. Dexamethasone inhibits early regenerative response of rat liver after cold preservation and transplantation. Hepatology 2003: 38: 1563.
31. Segev DL, Sozio SM, Shin EJ et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008: 14: 512.
32. Singh N, Gayowski T, Wannstedt CF et al. Interferon alpha therapy for hepatitis C virus recurrence after liver transplantation: long term response with maintenance therapy. Clin Transplant 1996: 10: 348.
33. Gayowski T, Singh N, Marino IR et al. Hepatitis C genotypes in liver transplant recipients: impact on post-transplant recurrence, infections, response to interferon-α therapy and outcome. Transplantation 1997: 64: 422.
34. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996: 23: 971.
35. Dickson RC, Caldwell SH, Ishitani MB et al. Clinical and histological patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996: 61: 701.
36. Eghtesad B, Fung JJ, Demetris AJ et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005: 11: 1343.
37. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995: 60: 225.
38. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
39. Miras M, Carballo F, Egea J et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 2007: 39: 2314.
40. Dumortier J, Gagnieu MC, Salandre J et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 2006: 12: 1342.
41. Robaeys G, Cassiman D, Verslype C et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc 2009: 41: 610.
42. Cantisani GP, Zanotelli ML, Gleisner AL et al. Enteric-coated mycophenolate sodium experience in liver transplant patients. Transplant Proc 2006: 38: 932.
43. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and auto-immune hepatitis. Liver Transpl Surg 1995: 1: 109.
44. Hayashi M, Keefe EB, Krams SM et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg 1998: 4: 208.